建發股份(600153.SH):廈門益悦收購合誠股份控制權的事項獲廈門市國資委批准
格隆匯8月6日丨建發股份(600153.SH)公佈,2021年8月6日,廈門益悦收到廈門市國資委出具的《關於廈門建發集團有限公司下屬建發國際全資子公司益悦置業收購合誠股份控制權事項的批覆》(廈國資辦〔2021〕161號),同意廈門益悦收購合誠股份控制權的事項。
同日,廈門益悦收到國家市場監督管理總局出具的《經營者集中反壟斷審查不實施進一步審查決定書》(反壟斷審查決定〔2021〕444),國家市場監督管理總局決定對廈門益悦收購合誠股份股權案不實施進一步審查。廈門益悦從即日起可以實施集中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.